Lunit

Company profile

About Lunit

Lunit is a global medical AI company transforming cancer detection and treatment through cutting-edge artificial intelligence. The company develops AI software that converts complex clinical data into actionable insights across the entire cancer care pathway, from early screening to precision oncology. Lunit's cancer screening portfolio includes INSIGHT MMG for 2D mammography, INSIGHT DBT for 3D breast imaging, and INSIGHT CXR for chest X-ray analysis, alongside the Volpara suite (Scorecard, Analytics, Live, Risk Pathways) for comprehensive breast imaging workflow management. In precision oncology, Lunit offers the SCOPE platform, including SCOPE IO for tumor microenvironment analysis, SCOPE IHC Suite for immunohistochemistry quantification (including uIHC, HER2, and PD-L1 biomarkers), and SCOPE GP for genotype prediction. The company's AI models are trained on diverse global datasets and designed for seamless integration into real-world clinical workflows. Lunit serves over 10,000 customer sites across 65+ countries, with its technology supported by 700+ publications and 100+ partnerships. The company works with health systems, radiologists, pathologists, and biopharma companies to accelerate oncology innovation from drug discovery through companion diagnostics. Lunit's mission is to enable earlier cancer detection and more precise treatment, ultimately improving patient outcomes through intelligent, scalable AI solutions.

Company description · Lunit official website

Mission. Working toward a future where cancer is detected earlier and treated with greater precision, enabling better outcomes for patients.